Invitrogen

Phospho-GYS1 (Ser641, Ser645) Polyclonal Antibody

Advanced Verification

This Antibody was verified by Cell treatment to ensure that the antibody binds to the antigen stated. View Details

2 Published Figures

4 References

View all (25) GYS1 antibodies

Datasheet

Questions & Answers

Datasheet

Questions & Answers

Product Image Gallery

Phospho-GYS1 (Ser641, Ser645) Antibody in Western Blot (WB) — Peptide Competition and Phosphatase Treatment Lysates prepared from 3T3-L1 cells left unstimulated (1), stimulated with Wortmanin for 90 minutes (2), stimulated with Wortmanin for 90 minutes plus insulin for 60 minutes (3), stimulated with insulin for 20

Phospho-GYS1 (Ser641, Ser645) Antibody in Cell treatment — Altered expression of target protein upon cell treatment demonstrates antibody specificity. Western blot using Anti-Phospho-GYS1 (Ser641, Ser645) Antibody (Product # 44-1092G) shows increase of GYS1 phosphorylation at Ser641 and Ser645 residues in U-87 MG, MCF-7 and L6 cell lines upon Cobalt chloride and Insulin treatments respectively. {TM}

Phospho-GYS1 (Ser641, Ser645) Antibody — Figure 6 Effects of inhibition of GSK-3beta on antimycin A-induced changes in DeltaPsi m and its recovery. A: Western blotting for Ser9-phospho- and total GSK-3beta in mitochondria, B: Effects of antimycin A (AA) on phospho-GSK-3beta level. C: TMRE fluorescence after AA treatment in vehicle- and LiCl-pretreated cells. Western blotting for Ser9-phospho-GSK-3beta, total GSK-3beta, Ser641/645-phospho-glycogen synthase (GS), non-phospho-GS and beta-actin (loading control) in total lysates of vehicle-treated and LiCl-treated cells. Treatments with 30 mM and 60 mM LiCl for 60 min induced phosphorylation of GSK-3beta and dephosphorylation of GS. Increased phosphorylation of GSK-3beta by LiCl reflects reduced activity of protein phosphatase 1, which is positively regulated by GSK-3beta activity. D: TMRE fluorescence after AA treatment in control siRNA- and GSK-3beta-siRNA-pretreated cells. NC = nicorandil. Treatment = time after onset of treatment with AA, Washout = time after washout of AA. *p<0.05 vs. Vehicle or Control siRNA. N = 8.

Product Details

Applications

Tested Dilution

Publications

Western Blot (WB)

1:500-1:1000

View 4 publications 4 publications

Product Specifications

Species Reactivity

Human, Mouse, Rat

Published species

Human, Mouse, Rat

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human Glycogen Synthase that contains serine 641 and serine 645. The sequence is conserved in human, mouse and rat.

Conjugate

Unconjugated

Form

Liquid

Purification

Antigen affinity chromatography

Storage buffer

Dulbecco's PBS, pH 7.3, with 50% glycerol, 1mg/mL BSA

Contains

0.05% sodium azide

Storage conditions

-20°C

RRID

AB_2533572

Target Information

Interacts with zinc finger protein A20/TNFAIP3 and inhibits TNF-induced NF-kappa-B-dependent gene expression by interfering with an RIP-or TRAF2-mediated transactivation signal. Increases cell surface CD4(T4) antigen expression. Interacts with HIV-1 matrix protein and is packaged into virions and overexpression can inhibit viral replication. May regulate matrix nuclear localization, both nuclear import of PIC (Preintegration complex) and export of GAG polyprotein and viral genomic RNA during virion production.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.